How U.K.'s approval of a Covid-19 vaccine will help restore public confidence: EL&N London founder

The U.K.’s groundbreaking decision to grant emergency approval to Pfizer and BioNTech’s coronavirus vaccine will likely lead other countries to quickly follow suit, according to one economist.

Regulators in the rest of Europe and the U.S. have yet to decide on granting emergency use of the vaccine, which was developed by the U.S. pharmaceutical giant and its German partner.

The U.K. government announced Wednesday that it had accepted a recommendation from the country’s independent drug regulator, the Medicines and Healthcare products Regulatory Agency, to approve the vaccine, which was seen to be 95% effective at preventing Covid infections in late-stage clinical trials.

The U.K. is the first to formally approve the Pfizer vaccine, its CEO calling the decision a “historic moment” in the fight against the pandemic.

“The U.K.’s approval will be only one of many, but along with that of the U.S. Food and Drug Administration and the European Medicines Agency, it is likely to set the pace for the rest of the world — and for the other vaccines that are awaiting approval,” said Ana Nicholls, managing editor of the Industry Briefing at The Economist Intelligence Unit.

“For the U.K., it means that the priority groups can now start to get vaccinations immediately: that includes healthcare workers and those in care homes (staff and residents) followed by other vulnerable groups — although given two doses are needed the effects won’t be felt until early next year.”

Pfizer and BioNTech only applied to the European Medicines Agency for the conditional marketing authorization of its vaccine on Tuesday. If the authorization is granted, it could enable its use in Europe this month, although that could prove ambitious given that the EMA said it would only complete its review of the vaccine by Dec. 29.

It also said it would conclude its review of Pfizer’s rival coronavirus vaccine, developed by Moderna and seen to be 94% effective at preventing Covid infection, by Jan. 12.

In the U.S., the FDA said late last month that it had scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee on Dec. 10 to discuss the Pfizer/BioNTech request for the emergency use authorization, so a decision could be announced soon after.

Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide.


Connect with CNBC News Online

#CNBC
#CNBCTV